Skip to main
CTSO

CytoSorbents (CTSO) Stock Forecast & Price Target

CytoSorbents (CTSO) Analyst Ratings

Based on 2 analyst ratings
Buy
Strong Buy 50%
Buy 0%
Hold 50%
Sell 0%
Strong Sell 0%

Bulls say

CytoSorbents is a leader in blood purification technology for the treatment of life-threatening conditions, and their proprietary polymer beads technology has a wide range of applications, including removing blood thinners during cardiothoracic surgery and treating critical illnesses. With strong distributor sales in the U.S. and Canada, as well as royalty income from HemoDefend ABG/RBC in the U.S., the company has shown a track record of consistent growth. The company has also taken steps to strengthen its balance sheet and reach profitability through margin improvement and cost reduction initiatives. Continued growth in the German market is expected to further support the company's financial success.

Bears say

CytoSorbents is facing increasing competition in the blood purification market and has been struggling to gain market share for their products. Despite promising applications in the removal of blood thinners during surgeries and treatment of critical illnesses, the company has not been able to consistently generate significant revenue. Additionally, the significant increase in the company's selling, general, and administrative costs over the past year may have a negative impact on their bottom line.

CytoSorbents (CTSO) has been analyzed by 2 analysts, with a consensus rating of Buy. 50% of analysts recommend a Strong Buy, 0% recommend Buy, 50% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of CytoSorbents and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About CytoSorbents (CTSO) Forecast

Analysts have given CytoSorbents (CTSO) a Buy based on their latest research and market trends.

According to 2 analysts, CytoSorbents (CTSO) has a Buy consensus rating as of Jul 15, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $5.38, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $5.38, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

CytoSorbents (CTSO)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.